Literature DB >> 3542619

Cholesterol and bile acid metabolism in middle-aged diabetics.

E Andersen, P Hellström, K Hellström.   

Abstract

Serum lipoproteins, bile and kinetics and net steroid balance were studied in 22 diet-treated and 5 insulin-treated patients with noninsulin-dependent diabetes mellitus, in 6 patients with insulin-dependent diabetes mellitus and in 15 normoglycemic controls. All subjects were middle-aged and the patients were hyperglycemic. Some of the diet-treated patients suffered from obesity and/or dyslipoproteinaemia mainly characterized by elevated levels of triglycerides and cholesterol in VLDL (very low-density lipoproteins). The diet-treated patients had enhanced fractional turnover of both cholic acid and chenodeoxycholic acid but bile acid formation was within the control range in all groups of patients. As the most significant finding net steroid balance (total cholesterogenesis) was raised in the diet-treated patients. Bile acid kinetics and net steroid balance were normal in insulin-treated patients irrespective of type of diabetes.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3542619

Source DB:  PubMed          Journal:  Diabete Metab        ISSN: 0338-1684


  3 in total

1.  Insulin sensitivity regulates cholesterol metabolism to a greater extent than obesity: lessons from the METSIM Study.

Authors:  Helena Gylling; Maarit Hallikainen; Jussi Pihlajamäki; Piia Simonen; Johanna Kuusisto; Markku Laakso; Tatu A Miettinen
Journal:  J Lipid Res       Date:  2010-05-01       Impact factor: 5.922

2.  Serum cholesterol and cholesterol and lipoprotein metabolism in hypercholesterolaemic NIDDM patients before and during sitostanol ester-margarine treatment.

Authors:  H Gylling; T A Miettinen
Journal:  Diabetologia       Date:  1994-08       Impact factor: 10.122

3.  The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study.

Authors:  Boyu Li; Yanjin Hu; Guang Wang; Lihong Liu
Journal:  BMC Pharmacol Toxicol       Date:  2020-06-15       Impact factor: 2.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.